BORACTIB 3 5 MG IV SC POWDER FOR SOLUTION FOR INJECTION 1 VIAL Specifications & 2026 Price
| Retail Price in Turkey | 18.980,07 TL |
|---|---|
| Drug Status | Active |
| Origin | Manufacture |
| Active Ingredient | Bortezomib |
| Manufacturer | Vem İlaç San. Ve Tic. Anonim Şirketi |
| Prescription Type | White Prescription |
|---|---|
| Packaging | 1 |
| Form | VIAL, IV-SC |
| Route of Admin. | Intravenous, Subcutaneous |
| Barcode | 8699844792589 |
Summary
BORACTIB® IV/SC POWDER CONTAINING VIAL FOR INJECTION SOLUTION 3.5 mg
It is applied intravenously or under the skin.
Active ingredient: 3.5 mg bortezomib (as mannitol boronic ester) in each vial (The diluted solution for intravenous administration contains 1 mg/mL bortezomib. The diluted solution for subcutaneous administration contains 2.5 mg/mL bortezomib).
Before you start using this medicine, read this INSTRUCTIONS FOR USE carefully, because it contains important information for you.
What is it used for?
Your doctor may administer BORACTIB® into a vein (intravenous) or under the skin (subcutaneous).
How to use?
Instructions for proper use and dosage/frequency of administration
Your doctor will determine the dose of your medicine depending on your disease and administer it to you.
The dose will be calculated based on your height and weight (body surface area).
The usual starting dose is 1.3 milligrams per square meter of body surface area twice a week. Your doctor may change the dose and the total number of treatment periods (cure) depending on your response to treatment, adverse effects that occur during treatment, and your other underlying diseases. Progressive (progressing-worsening) multiple myeloma
When BORACTIB® is used alone, a treatment period consists of a total of 4 doses. Doses are given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a 10-day treatment-free ‘rest period’. Therefore, a treatment period (cycle) consists of 21 days (3 weeks). You can take a maximum of 8 terms (24 weeks).
Side Effects
Like all medicines, side effects may occur in people who are sensitive to the ingredients contained in BORACTIB®.
If you are being prescribed BORACTIB® for multiple myeloma or mantle cell lymphoma, tell your doctor immediately if you notice any of the following symptoms:
Treatment with BORACTIB® can very commonly lower the levels of your red blood cells, white blood cells and platelets (clotting cells) in your blood. Therefore, you will have regular blood tests before and during your treatment to check whether your blood cell count is normal.
You may experience a decrease in the number of:
Side effects are classified as shown in the following categories;
🇹🇷 Frequently Viewed Medicines in Turkey (2026 Prices)
Tourists also checked the prices of these medicines: